Ablynx Ups Profile Stateside With $200m Nasdaq Listing
Success in the clinic with caplacizumab for aTTP and a big IPO in the USA has put the Belgium-headquartered group in the spotlight.
You may also be interested in...
A little over 12 months ago, Belgian Nanobody biotech Ablynx was at the center of a bidding war between Novo Nordisk and Sanofi. Ex-Ablynx CEO Edwin Moses talked to Scrip about the four-month period that changed the course of the company.
Products in the final stages of pre-marketing evaluation at the European Medicines Agency include drugs for influenza, NSCLC, aTTP and HIV infection.
Highlights of the upcoming American Society of Hematology meeting include updated data for CAR-T therapies, pivotal results moving major brands into bigger markets, PD-1 inhibitors branching out into new types of hematological malignancies and dueling gene therapies in hemophilia.